Caricamento quotazioni...
Previsioni
| Acquista |
0 |
| Mantieni |
1 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Ontex reports sales decline in 2025 and targets 10% EBITDA growth for 2026
Ontex recorded a sales decline in 2025 to €1,762m and an adjusted EBITDA of €176m (margin 10.0% vs. 12.0% in 2024), driven by weak baby-care demand, higher raw material costs and operational disruptions. The company posted an overall loss of €174m, which included a €190m loss from discontinued operations, and generated a negative free cash flow of -€25m. Net debt fell to €577m, but the leverage ratio rose to 3.3x. For 2026 Ontex expects broadly stable sales, a 10% increase in adjusted EBITDA, a return to positive free cash flow and a reduction of leverage to around 3.0 or below; measures include cost transformation, efficiency improvements and a strategic review. » Altro su de.investing.com
Ontex accelerates CEO change and launches comprehensive strategy review
Ontex has brought forward the leadership change: Laurent Nielly assumes the role of CEO with immediate effect, while Gustavo Paz will remain until the end of January to facilitate the handover. The company announced a full strategic review of its portfolio, operational setup and distribution channels and has established a strategy committee of the board. The measures are aimed at higher cash generation and improved returns; the announcement sent the share price markedly higher. » Altro su de.investing.com
S&P cuts outlook for Ontex to stable after second profit warning
S&P Global Ratings has downgraded the outlook for Ontex from “positive” to “stable”; the B+ rating remains unchanged. The move follows a second profit warning for 2025 with a lowered sales forecast (core markets: −4 to −6 %) and adjusted EBITDA of €175–180m. S&P expects a reported sales decline of around 14% in 2025, an EBITDA margin of about 7.5% and no positive free operating cash flow. For 2026 S&P anticipates a moderate recovery (sales ~€1.79–1.80bn, adjusted EBITDA margin towards 10% and FOCF around €30m); Ontex also plans a €200m cost-efficiency program for 2026–2028. » Altro su de.investing.com
Ontex warns of weaker 2025 performance and stock drops sharply
Ontex's shares fell about 18% after a profit warning for 2025 and the announcement of a CEO succession. The company now expects a mid-single-digit decline in like-for-like sales and has revised adjusted EBITDA to €175–180m (previously €200–210m), well below the analyst consensus. Reasons are weaker consumer demand in the European baby care business and lower volumes from new contracts; free cash flow is expected to show an outflow of €35m in 2025 and net debt is forecast to rise to 3.2x EBITDA. Ontex plans an efficiency programme targeting €200m in savings over three years; Laurent Nielly will succeed Gustavo Calvo Paz as CEO on 5 May 2026. » Altro su de.investing.com
Ontex reports Q3 2025: sales fall year-on-year, sequential recovery visible
Ontex reported Q3 2025 sales of €445 million (-3.8% like‑for‑like year‑on‑year) with a sequential improvement of 3.7% versus the prior quarter. Adjusted EBITDA margin was 11.4%, adjusted EBITDA amounted to €51 million (vs. €56 million a year earlier); cost‑saving measures delivered €16 million in savings. Baby care volumes remained weak, while adult and feminine hygiene showed volume growth. Net debt stood at €543 million with a leverage ratio of 2.7x. Ontex reaffirmed its full‑year guidance (adjusted EBITDA €200–210 million, free cash flow around €0, leverage ~2.5x) and expects roughly 5% sales growth in Q4 and an EBITDA improvement of more than €13 million compared with Q3. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giugno 2026 | YoY |
|---|---|---|
| Ricavi | 854,8 Mln | - |
| Utile lordo | 232 Mln | - |
| Utile netto | -143 Mln | - |
| EBITDA | 78,2 Mln | - |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 118,4 Mln € |
Numero di azioni | 80 Mln |
Massimo/minimo a 52 settimane | 6,72 € - 1,31 € |
| Dividendi | No |
Beta | 0,55 |
Rapporto P/E | -0,59 |
Rapporto PEG | 0,01 |
Rapporto P/B | 0,14 |
Rapporto P/S | 0,07 |
Profilo aziendale
Ontex Group NV fornisce soluzioni per l'igiene personale per la cura del bambino, la cura femminile e la cura degli adulti in Europa occidentale, Europa orientale, Americhe, Messico, Regno Unito, Italia, Francia e a livello internazionale. Offre prodotti per la cura del bambino, come pannolini e mutandine per bambini e salviette umidificate, con i marchi Baby Pants, Bbtips, Bio Baby, Chicolastics, Canbebe, Cremer Disney, Helen Harper, Kiddies, Little Big Change, Moltex, Pom Pom, Sapeka e Mônica; e prodotti per la cura femminile, tra cui assorbenti igienici, salvaslip e tamponi, con i nomi di marca Fiore, Mia, NAT, Sincere e Silhouette. L'azienda fornisce inoltre prodotti per l'incontinenza degli adulti, comprendenti mutandine e pannoloni per adulti, traverse per incontinenza e prodotti per la protezione del letto, con i marchi A Lovely Day, Adultmax Maturidade, Affective, Bigfral, iD, Canped, Affective, Lille Healthcare, Kylie, Serenity, Orizon e Moviment; e produce e vende mascherine per il viso. Vende i propri prodotti a consumatori, rivenditori e fornitori di assistenza sanitaria istituzionali e privati, oltre a offrire prodotti con marchi della distribuzione. Ontex Group NV è stata fondata nel 1979 ed ha sede a Aalst, in Belgio.
| Nome | Ontex Group |
| CEO | Laurent Nielly |
| Sede centrale | Aalst,
vlg Belgio |
| Sito web | |
| Settore | Beni di prima necessità |
| Industria | Prodotti per la cura della persona |
| Quotazione in borsa | 25/06/2014 |
| Dipendenti | 5000 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Euronext | ONTEX.BR |
Pnk | ONXXF |
Brussels Stock Exchange | ONTEX.BR |
Frankfurt | OT7.F |
Düsseldorf | OT7.DU |
London | 0QVQ.L |
München | OT7.MU |
Wien | ONTX.VI |